Loading organizations...
iGan Partners is a Toronto, Ontario, Canada-based venture capital firm, founded in 2013 by Sam Ifergan. The firm invests in early-stage healthcare technologies, including AI-enabled medical devices, digital health, and medtech, with a core focus on improving patient outcomes and reducing healthcare costs. Targeting North American companies in pre-commercial or commercial stages, iGan makes post-seed and Series A investments ranging from $1-5 million. Notably, iGan Partners raised CAD $100 million for its iGan Fund I in April 2018, surpassing its initial goal and establishing itself as a prominent healthcare VC investor in Canada. Its impressive portfolio features companies like eSight, MolecuLight, and Exact Imaging, and the firm has successfully overseen six exits. A recent strategic partnership with Medical Alley in September 2024 further underscores its commitment to scaling innovative medical devices and digital health startups across the US and Canada.
Key people at iGan Partners.
Key people at iGan Partners.
iGan Partners is a leading healthcare-focused venture capital firm based in Toronto, Canada, specializing in early-stage investments in AI-enabled MedTech and Digital Health.[1][4] The firm's mission is to empower visionary founders with smart capital, active support, and access to industry networks to commercialize disruptive technologies, scale high-impact companies, and improve patient outcomes while reducing healthcare costs.[1][3][4] Its investment philosophy emphasizes long-term company building through operator expertise, data-driven decisions, and partnerships with sector-specific co-investors, targeting Seed to Series A stages primarily in Canada, the US, and Israel.[2][3][5] Key sectors include digital health, medical devices, diagnostics, and AI-driven therapeutics, with a portfolio featuring companies like Exact Imaging (micro-ultrasound for prostate imaging), MolecuLight (wound imaging), RetiSpec (Alzheimer's diagnostics), Segmed (real-world imaging data), Cosm Medical, and Cyborg.[1][3][6] iGan has significantly impacted the startup ecosystem by providing not just funding but strategic guidance, enabling job creation, global scaling, and exits in healthcare innovation.[2][6]
iGan Partners emerged as one of Canada's largest healthcare-dedicated VC firms, with roots in supporting early healthcare disruptors, as evidenced by investments dating back to at least 2012 in companies like MolecuLight.[1][6] Key partners include Sam Ifergan, a former engineer-turned-entrepreneur-investor who has led deals and provided hands-on involvement; Olivier Giner, Kuljeev Singh, Gregory Ogorek, and Ethan Laniado, bringing combined expertise as entrepreneurs, operators, and investors with over 50 deals across tech and healthcare in North America and Europe.[5][6] The firm's evolution has centered on honing a focus on AI-enabled MedTech and Digital Health, expanding from seed-stage support to follow-on funding through exits, while leveraging a team-first approach to nurture scientist-founders amid growing demand for healthcare tech commercialization.[4][5][6]
iGan Partners rides the wave of AI-driven healthcare transformation, capitalizing on trends like precision diagnostics, real-world data analytics, and point-of-care devices amid rising demand for cost-effective, patient-centric solutions.[1][3] Timing is ideal post-2020s acceleration in digital health adoption, fueled by aging populations, post-pandemic telehealth shifts, and AI advancements reducing diagnostic errors—market forces favoring early-stage VCs with healthcare domain knowledge.[2][4] The firm influences the ecosystem by bridging Canadian innovation hubs with US/Israeli tech, empowering non-traditional founders (e.g., scientists), and fostering cross-border scaling that amplifies North American leadership in MedTech.[5][6]
iGan Partners is poised to deepen its portfolio in AI-MedTech amid exploding demand for Alzheimer's tools, wound care, and confidential AI for regulated data, with recent 2025 deals signaling momentum into personalized care and imaging.[3] Trends like multimodal AI diagnostics and global health data interoperability will shape its trajectory, potentially driving more unicorns as regulatory tailwinds (e.g., FDA AI approvals) ease paths to market. Its influence may evolve toward larger funds and LP syndicates, solidifying Toronto as a MedTech powerhouse while sustaining hands-on founder empowerment that sparked its rise from 2012 bets to ecosystem leader.[6]
iGan Partners has 5 tracked investments across 4 companies. The latest tracked deal is $10.0M Venture Round in Exact Imaging in February 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 10, 2026 | Exact Imaging | $10.0M Venture Round | IGan Partners | — |
| Sep 1, 2024 | Segmed | $10.0M Series A | Advocate Health, IGan Partners | Blumberg Capital, Nina Capital |
| Mar 26, 2019 | Finaeo | $5.3M Other Equity | Karim Gillani | Christian Lassonde, Inovia Capital, Rgax, Rising Tide Fund |
| Sep 1, 2017 | Finaeo | $2.0M Seed | Impression Ventures | TOM Williams, 500 Startups, Robot Ventures |
| Jan 1, 2016 | Limelight Platform | $2.0M Seed | IGan Partners | Hyde Park Venture Partners, Dave Knox, ROB Mcdonald, Trevor Wright, Jason Tryfon, Forum Ventures, Hyde Park Ventures, Sand Hill Angels |
